"I Refused Statins My Whole Life… Then I Had a Heart Attack at 36"
What this means—and what your real options are
Bob had seen questions like this before.
As an accountant, he liked numbers. Patterns. Things that added up.
But this one didn’t.
Karen read it aloud from her phone, the way she always did when something caught her attention mid-scroll:
“I have familial and polygenic hypercholesterolemia. I avoided statins my whole life. Then I had a heart attack at 36. Diet and exercise haven’t worked for me. Are there any alternatives to statins?”
The table got quiet.
Lisa, the biology teacher, didn’t hesitate.
“This isn’t lifestyle cholesterol,” she said. “This is genetic. The rules are different.”
When Cholesterol Isn’t About Lifestyle
Most cholesterol advice assumes one model: eat better, move more, and your numbers will follow.
For most people, that’s true.
But familial hypercholesterolemia (FH) operates by different rules entirely.
FH is a genetic condition that impairs the body’s ability to clear LDL cholesterol from the bloodstream. It is largely independent of willpower or discipline. The liver simply lacks enough functional LDL receptors to do the job. So cholesterol accumulates—continuously, silently—regardless of what you eat or how often you exercise.
That’s why someone can:
• Eat a clean, low-fat diet for years
• Exercise consistently
• Maintain a healthy weight
• Do everything the guidelines recommend
…and still have dangerously elevated LDL contributing to early atherosclerotic plaque development.
A heart attack at 36 isn’t a failure. It’s what untreated FH can look like.
Polygenic Hypercholesterolemia: The Other Piece
The original question mentions both familial and polygenic hypercholesterolemia. These are related—but not identical—conditions.
Familial hypercholesterolemia (FH) is typically caused by a single dominant gene mutation—often in the LDL receptor gene (LDLR), the ApoB gene, or PCSK9. It tends to produce very high LDL levels from birth.
Polygenic hypercholesterolemia is different. It reflects the combined effect of many small genetic variants—each one modest on its own—that together push LDL higher than it would otherwise be. It’s subtler but still significant, and it still doesn’t respond well to lifestyle intervention alone.
Having both is a compounding challenge. The genetic burden is high, and the body is working against conventional correction from multiple angles.
Why the Question Is Legitimate
Statins are the standard first-line treatment for FH—and for most people, they work well. They reduce LDL production in the liver and significantly lower cardiovascular risk.
But not everyone tolerates them.
Muscle pain (myalgia) and muscle weakness affect a meaningful percentage of patients. Some experience fatigue, cognitive fog, or liver enzyme elevations that require stopping the medication. Statins reduce circulating CoQ10 levels as a consequence of inhibiting the mevalonate pathway. Whether this directly causes muscle symptoms remains debated, but the overlap with energy metabolism has made it an area of ongoing interest.
Asking “is there anything else?” is not avoidance. It’s a reasonable medical question—and one that has real answers.
Alternatives and Additions to Statins
Several evidence-based options exist, and in many cases they work best in combination with—or as substitutes for—statin therapy.
Ezetimibe
Works differently than statins—it blocks cholesterol absorption in the small intestine rather than reducing liver production. Often used alongside statins for additive effect, or alone when statins aren’t tolerated. Well-established, generally well-tolerated.
PCSK9 Inhibitors (Evolocumab, Alirocumab)
Injectable biologics that dramatically increase the liver’s ability to clear LDL from the bloodstream. Can reduce LDL by 50–60% on top of other therapies. Approved specifically for FH and high-risk cardiovascular patients. The main barrier is cost, though insurance coverage for FH is increasingly available.
Inclisiran
A newer RNA-based therapy that targets PCSK9 at the gene expression level. Administered as an injection twice a year. Effective for those who cannot tolerate daily medications or prefer less frequent dosing.
Bempedoic Acid
A non-statin oral medication that reduces LDL by inhibiting an enzyme upstream from the pathway statins target. Importantly, it does not activate in muscle tissue the way statins do—which means it may be better tolerated by people who experience statin-related muscle pain.
LDL Apheresis
A dialysis-like procedure that physically removes LDL from the blood. Reserved for severe FH cases, particularly homozygous FH, where LDL levels remain extremely elevated despite maximum medical therapy. Not a first line—but a genuine option when others fall short.
The Nutrient Depletion Factor
Even when statins are the right choice—and for many FH patients, they are—there’s a layer of the conversation that doesn’t get enough attention.
Statins inhibit the mevalonate pathway, which produces not only cholesterol but also CoQ10 (ubiquinone)—a compound essential for mitochondrial energy production. The depletion is measurable in blood and muscle tissue. Whether it causes the muscle symptoms many patients experience remains debated in the research literature, but it is real, and some patients report meaningful improvement when supplementing.
This raises a broader question underneath the pharmacology: when a treatment alters a biological pathway, what does the body need to stay balanced?
For FH patients on long-term lipid-lowering therapy, that question is worth asking—and answering—with a physician who understands both the cardiovascular picture and the broader metabolic context.
Back at the Table
Bob leaned back in his chair.
“So statins weren’t the problem,” he said slowly. “Not treating it was.”
“For some people, yes,” Lisa said. “And the good news is, the toolbox has gotten a lot bigger. Statins aren’t the only option anymore—but the goal is the same. Get the LDL down. Keep it there. And make sure the rest of the body isn’t paying a price it doesn’t have to pay.”
About the characters
Bob, Karen, and Lisa are characters from Living Well on Statins, a health education book available on Amazon. The scenarios depicted are illustrative; they are not a substitute for personalized medical advice. If you have familial hypercholesterolemia or elevated cardiovascular risk, please work with a qualified physician to determine the right treatment approach for your situation.
Christian Junge is the founder of Solprana, a supplement and wellness brand focused on homeostasis and nutrient replenishment. Learn more at solprana.net.